Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Has 'Substantial Doubts' About Its Ability to Stay in Business; May Need to Raise Cash to Stay Afloat

NEW YORK (GenomeWeb News) — Ciphergen Biosystems and its outside auditor are concerned that the company may not be able to continue operating as a going concern, the firm said in its annual report it filed with the US Securities and Exchange Commission.  
 
“We believe that our current cash balances may not be sufficient to fund planned expenditures,” Ciphergen reported in the filing, released on April 2. “This raises substantial doubt about our ability to continue as a going concern.
 
“During 2007, we may have to raise additional funds through the issuance of equity or debt securities, or a combination thereof, in the public or private markets in order to continue operations,” the company added.
 
The company’s auditor, PriceWaterhouseCoopers, gave a similar opinion in the filing.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.